Loading stock data…
ADMA
$10.52+0.27 (+2.63%)
Market ClosedLast close May 1
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ADMA Biologics, Inc. in the Healthcare sector is trading at $10.52. The stock is currently near its 52-week low of $7.21, remaining 33.5% below its 200-day moving average. Technical signals show neutral RSI of 53 and bullish MACD crossover, explaining why ADMA maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.52
Potential Upside
46.6%
Whystock Fair Value$15.42
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.25
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
43.77%
Volume
Today's trading volume
3.54M
Recent News
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know
Adma Biologics (ADMA) closed at $10.6 in the latest trading session, marking a -2.75% move from the prior day.
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Canaccord’s Support and Short-Seller Rebuttal Could Be A Game Changer For ADMA Biologics (ADMA)
Recently, Canaccord Genuity initiated coverage on ADMA Biologics with a positive view, while the company addressed a short-seller report by rejecting its claims and highlighting strong demand for its immune globulin portfolio, including ASCENIV. This combination of external endorsement and management’s firm defense of product demand and profitability trends offers investors fresh information on how ADMA views its competitive and operational position. Next, we’ll examine how ADMA’s rebuttal...
ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ADMA Biologics, Inc. is one of the best biotech stocks to invest in. TheFly reported on April 21 that Canaccord Genuity initiated coverage of ADMA with a Buy rating and set a price target of $21. The firm highlighted an […]
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.